179 related articles for article (PubMed ID: 30003661)
21. Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.
Dongamanti A; Aamate VK; Devulapally MG; Gundu S; Balabadra S; Manga V; Yogeeswari P; Sriram D; Balasubramanian S
Mol Divers; 2017 Nov; 21(4):999-1010. PubMed ID: 28840414
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors.
Suresh A; Srinivasarao S; Agnieszka N; Ewa AK; Alvala M; Lherbet C; Chandra Sekhar KVG
Chem Biol Drug Des; 2018 Jun; 91(6):1078-1086. PubMed ID: 29063733
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases.
Narender M; Jaswanth S B; Umasankar K; Malathi J; Raghuram Reddy A; Umadevi KR; Dusthackeer AVN; Venkat Rao K; Raghuram R A
Bioorg Med Chem Lett; 2016 Feb; 26(3):836-840. PubMed ID: 26755393
[TBL] [Abstract][Full Text] [Related]
24. Effective GTP-replacing FtsZ inhibitors and antibacterial mechanism of action.
Artola M; Ruiz-Avila LB; Vergoñós A; Huecas S; Araujo-Bazán L; Martín-Fontecha M; Vázquez-Villa H; Turrado C; Ramírez-Aportela E; Hoegl A; Nodwell M; Barasoain I; Chacón P; Sieber SA; Andreu JM; López-Rodríguez ML
ACS Chem Biol; 2015 Mar; 10(3):834-43. PubMed ID: 25486266
[TBL] [Abstract][Full Text] [Related]
25. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
26. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.
Park B; Awasthi D; Chowdhury SR; Melief EH; Kumar K; Knudson SE; Slayden RA; Ojima I
Bioorg Med Chem; 2014 May; 22(9):2602-12. PubMed ID: 24726304
[TBL] [Abstract][Full Text] [Related]
28. A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ.
Reynolds RC; Srivastava S; Ross LJ; Suling WJ; White EL
Bioorg Med Chem Lett; 2004 Jun; 14(12):3161-4. PubMed ID: 15149666
[TBL] [Abstract][Full Text] [Related]
29. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and docking studies of some novel (R)-2-(4'-chlorophenyl)-3-(4'-nitrophenyl)-1,2,3,5-tetrahydrobenzo[4,5] imidazo [1,2-c]pyrimidin-4-ol derivatives as antitubercular agents.
Barot KP; Jain SV; Gupta N; Kremer L; Singh S; Takale VB; Joshi K; Ghate MD
Eur J Med Chem; 2014 Aug; 83():245-55. PubMed ID: 24972340
[TBL] [Abstract][Full Text] [Related]
31. MoS
Raghu MS; Pradeep Kumar CB; Prasad KNN; Prashanth MK; Kumarswamy YK; Chandrasekhar S; Veeresh B
ACS Comb Sci; 2020 Oct; 22(10):509-518. PubMed ID: 32806898
[TBL] [Abstract][Full Text] [Related]
32. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
33. BT-benzo-29 inhibits bacterial cell proliferation by perturbing FtsZ assembly.
Ray S; Jindal B; Kunal K; Surolia A; Panda D
FEBS J; 2015 Oct; 282(20):4015-33. PubMed ID: 26258635
[TBL] [Abstract][Full Text] [Related]
34. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological activity evaluation of novel 2,6-difluorobenzamide derivatives through FtsZ inhibition.
Bi F; Guo L; Wang Y; Venter H; Semple SJ; Liu F; Ma S
Bioorg Med Chem Lett; 2017 Feb; 27(4):958-962. PubMed ID: 28082038
[TBL] [Abstract][Full Text] [Related]
36. Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
Reshma RS; Jeankumar VU; Kapoor N; Saxena S; Bobesh KA; Vachaspathy AR; Kolattukudy PE; Sriram D
Bioorg Med Chem; 2017 May; 25(10):2761-2771. PubMed ID: 28389113
[TBL] [Abstract][Full Text] [Related]
37. A novel quinoline derivative that inhibits mycobacterial FtsZ.
Mathew B; Ross L; Reynolds RC
Tuberculosis (Edinb); 2013 Jul; 93(4):398-400. PubMed ID: 23647650
[TBL] [Abstract][Full Text] [Related]
38. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
[TBL] [Abstract][Full Text] [Related]
39. A microwave-assisted facile regioselective Fischer indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles.
Karthikeyan SV; Perumal S; Shetty KA; Yogeeswari P; Sriram D
Bioorg Med Chem Lett; 2009 Jun; 19(11):3006-9. PubMed ID: 19403307
[TBL] [Abstract][Full Text] [Related]
40. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
